A Phase 1b, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naive Patients With Acute Myelogenous Leukemia Who Are 60 Years or Older

Trial Profile

A Phase 1b, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naive Patients With Acute Myelogenous Leukemia Who Are 60 Years or Older

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Pevonedistat (Primary) ; Azacitidine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 06 Dec 2016 Updated safety and efficacy results for the maximum tolerated dose cohort presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 03 Nov 2016 According to a Takeda media release, data from this trial will be presented at the 58th American Society of Hematology (ASH) Annual Meeting
    • 07 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top